Publications
- Chapter Three - Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents2017 | Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis2016 | Second Faculty of Medicine
- Flt3 ligand expands CD4+FoxP3+regulatory T cells in human subjects2013 | Second Faculty of Medicine
- Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy2013 | Second Faculty of Medicine
- Type I interferon and cancer2024 | Second Faculty of Medicine
- Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma2023 | First Faculty of Medicine, Second Faculty of Medicine
- Trial watch: chemotherapy-induced immunogenic cell death in oncology2023 | Second Faculty of Medicine
- Interferon signaling restrains renal cell carcinoma heterogeneity2023 | Second Faculty of Medicine
- Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial2022 | First Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University, Third Faculty of Medicine, Faculty of Medicine in Pilsen
Loading network view...
